



1614
12462
Attorney Docket No. 078061-31851

I hereby certify that this correspondence (and any paper or fee referred to as being transmitted herewith) via first class mail in an envelope addressed to the ASSISTANT COMMISSIONER OF PATENTS, WASHINGTON, D.C. 20231, on

November 18, 2002
(Date)

Traci Calderon 11/18/02
(Signature and Date)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Patent Application of:

Morton J. Seligman

Serial No. : 10/061,025

: Art Unit : 1614

Filed : January 30, 2002

: Examiner : Unassigned

Title : COMPOSITIONS AND METHODS
FOR TREATING ALLERGIC FUNGAL
SINUSITIS

RECEIVED

NOV 22 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents and Trademarks
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. 1.97-1.99, applicants respectfully request that the following references be made of record in the above-identified application:

Other Documents

Cody et al., "Allergic Fungal Sinusitis: The Mayo Clinic Experience," *Laryngoscope*, **104**:1074-1079 (1994).

Leff et al., "Rationale For the Use of Leukotriene Modifiers in the Treatment of Asthma," *Asthma 2000 Monograph Series*, 20-24 (2000).

Leff et al., "Efficacy and Safety of Antileukotrienes," *Asthma 2000 Monograph Series*, 25-33 (2000).

"Montelukast Approved for Asthma in Adults and Children," *Medical Sciences Bulletin* (internet - pharmainfo.com), **246** (1998).

"SINGULAIR: Important Prescribing Information," *Med Watch News* (internet - pharmainfo.com), (December 4, 1998).

deShazo et al., "Diagnostic Criteria For Allergic Fungal Sinusitis," *Journal of Allergy Clinical Immunology*, **96(1)**:24-35 (1995).

Siegel, Charles, "Grass Pollen Injection Immunotherapy: Effects on Cytokine mRNA Expression in the Nasal Mucosa During the Pollen Season," *Journal of Allergy Clinical Immunology, Abstract 710* (February 2001).

El-Akkad, T., et al., "Triamcinolone the Drug of Choice With Patients," *Post Graduate Course American Academy of Allergy, Asthma and Immunology, New Orleans, LA* (March 2001).

Storms, William, "Rethinking our Approach to Allergic Rhinitis Management," *Annals of Allergy, Asthma and Immunology*, **88**:30-35 (2002).

Meltzer, Eli, "Clinical Evidence for Antileukotriene Therapy in the Management of Allergic Rhinitis," *Annals of Allergy, Asthma and Immunology*, **88**:23-29 (2002).

Borish, Larry, "The Role of Leukotrienes in Upper and Lower Airway Inflammation and the Implications for Treatment," *Annals of Allergy, Asthma and Immunology*, **88**:16-22 (2002).

Holgate, S., et al., "Chapter 13 - Measurements of Leukotrienes in Asthma," *SRS-A to Leukotrienes - The Dawning of a New Treatment*, 212-234 (1996).

Holgate, S., et al., "Chapter 3 - The Discovery of Leukotrienes," *SRS-A to Leukotrienes - The Dawning of a New Treatment*, 45, 107, 156, 172, 177 and 179 (1996).

Copies of the aforementioned publications are submitted herewith along with a completed form PTO-1449. The references are listed on form PTO-1449.

Consideration of this Information Disclosure Statement is respectfully requested, since the information provided herein may be material to the patentability of the subject application as defined in 37 C.F.R. §1.56. The submission of references with this Information Disclosure Statement should not be construed by the Examiner that a comprehensive search through the prior art was conducted; it is requested that the Examiner make such a comprehensive search.

The above citations do not constitute an admission that the references are relevant or material to the claims; they are cited only as constituting the closest art of which applicant is aware. As such, it is respectfully submitted that the Claims presented for examination define patentable subject matter thereover. Favorable consideration on the merits is respectfully requested.

Fees

Pursuant to 37 C.F.R. §1.97(c), since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fees are believed to be necessitated by this Information Disclosure Statement. Should any fee be required, please charge the required fee to Deposit Account No. 03-3839.

Thank you for your consideration.

Date: 7/18/02



William H. Epstein
Attorney for Applicant
Registration No. 20,008

Gibbons, Del Deo, Dolan,
Griffinger & Vecchione
One Riverfront Plaza
Newark, New Jersey 07102
(973) 596-4500